Compare iShares MSCI Taiwan ETF (EWT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Taiwan ETF trades at $107.33 (market cap $12.49B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares MSCI Taiwan ETF is the larger of the two by market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 53 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWT | SYRE | |
|---|---|---|
Market Cap | $12.49B | $7.52B |
Volume | 5,965,495 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $108.92 |
52-Week Low | $60.03 | $22.18 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.46, down 0.71% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of holdings. Recent news highlights Taiwan's strategic position in AI chip manufacturing with companies planning $20 billion in US investments.
The ETF offers exposure to Taiwan's dominant semiconductor industry but faces significant geopolitical risks. Strong AI-driven fundamentals and reasonable tech valuations support upside potential, though China-Taiwan tensions represent a persistent overhang. Institutional interest remains positive with Bank of America increasing its stake by 22.4% in the latest quarter.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
